Red Nucleus has acquired Bridge Medical Consulting, a specialized health economics and outcomes research (HEOR) consultancy, as the company deepens its value, evidence, and market access offerings for biopharmaceutical clients facing heightened scrutiny around drug pricing, value demonstration, and reimbursement decisions. Red Nucleus said the deal strengthens its ability to help customers prove the clinical and economic value of increasingly specialized therapies amid complex regulatory and payer requirements.
Founded in 2011, Bridge Medical Consulting supports pharmaceutical and biotechnology companies across Europe and the United States, with services spanning evidence synthesis, integrated evidence planning, population insights, health economic modeling, and statistics. Red Nucleus said Bridge also offers AI-enabled workflows that deliver decision-grade evidence more efficiently while maintaining scientific rigor.
Red Nucleus expects the combination to broaden its end-to-end HEOR support, including systematic literature reviews and indirect treatment comparisons, evidence planning and generation, economic modeling, statistics, real-world evidence research, and strategic advisory. Bridge Medical Consulting will be merged with Red Nucleus’s existing HEOR business under Monique Martin, Global Head of HEOR, within Red Nucleus’s broader Value & Evidence organization.
KEY QUOTES
“With payers and regulators placing unprecedented scrutiny on drug pricing and value, HEOR has become mission-critical for life sciences companies. This acquisition enhances our ability to support clients across value, evidence, and market access. Bridge Medical Consulting’s expertise, culture, and forward-looking approach to technology make them an exceptional fit for Red Nucleus, and we’re excited to welcome their team.”
Mike Menta, Chief Executive Officer, Red Nucleus
“Joining Red Nucleus allows us to scale our impact and offer clients a broader, more integrated set of services. We share a commitment to scientific excellence and to thoughtfully applying AI and related technologies to enhance rigor and efficiency, while keeping expert judgment at the center of our work. The combined platform brings together complementary expertise that will benefit customers of both companies.”
Paul Gandhi, Founder and Chief Executive Officer, Bridge Medical Consulting
“I am very excited to partner with the brilliant Bridge Medical Consulting team who bring a range of HEOR capabilities to Red Nucleus. I have been particularly impressed by their robust and transparent approach to developing applied AI solutions, especially to decision-grade SLRs, combining the best of AI with the best of humans to yield the highest quality client outputs. From the high uptake of Bridge Medical’s AI-enabled offerings, it is clear that clients also value this innovative, robust, and transparent approach,”
Monique Martin, Global Head of HEOR, Red Nucleus
